Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Necitumumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Necitumumab - Eli Lilly and Company

Alternative Names: IMC-11F8; LY 3012211; Portraza; Portrazza

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImClone Systems
  • Developer AstraZeneca; Eli Lilly and Company; ImClone Systems; Nippon Kayaku
  • Class Antineoplastics; Fab fragments; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Lung cancer; Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours in Netherlands (IV, Infusion)
  • 06 Nov 2024 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in France, South Korea, Taiwan, Japan, Italy, USA (IV)
  • 06 Nov 2024 Discontinued - Phase-I for Solid tumours in Japan (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top